Study to Evaluate the Safety of SP-104

Healthy Volunteers Clinical Trial

Official title:

Phase 1, Double-blind, Randomized, 2-Period, 2-Treatment Crossover Study to Evaluate the Safety of SP-104 Compared to Immediate Release Naltrexone Capsules in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04958876
• Other study ID #: SP-104-02
• Status: Completed
• Phase: Phase 1
• Start date: October 4, 2021
• Est. completion date: December 20, 2021

Study information

• Verified date: January 2022
• Source: Scilex Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.

Description:

The purpose of this trial is to evaluate the safety and tolerability of SP-104 relative to naltrexone immediate release capsules in healthy adults. The study is designed to test the hypothesis that the formulation of SP-104 will mitigate against adverse events associated with naltrexone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: December 20, 2021
• Est. primary completion date: December 20, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Able and willing to read, write, and understand the English language and provide English language written informed consent (IC) prior to beginning any study procedures.

2. Male or female age 18 to 70 years (inclusive) at screening.

3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiogram (ECG), as deemed by the Investigator.

4. Negative urine drug screen for drugs of abuse, including cocaine, marijuana, amphetamines, and barbiturates at the Screening Visit and at each check-in.

5. If female, heterosexually active, of childbearing potential, not pregnant, not trying to become pregnant, or lactating, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 30 days after the last study dose. A second non-hormonal method of contraception is required if a hormonal form of birth control is used. Females of childbearing potential must have negative pregnancy tests at Screening and on admission.

6. If male and heterosexually active, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 90 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 90 days after the last study dose.

7. Able to swallow capsules.

8. Agrees to comply with all study requirements throughout the entire study period.

Exclusion Criteria:

1. A body mass index (BMI) <18 kg/m2 or >30 kg/m2 (without rounding).

2. Are using prescription medications or over-the-counter products (including dietary supplements such as vitamins, minerals, herbs or other botanicals, amino acids, enzymes (extracts or concentrates), or probiotics (bacteria or yeasts), within 14 days prior to administration of the study medication.

3. Currently using or have recently used opioids

4. Use of any other investigational drug within 30 days prior to administration of the study medication.

5. History of allergic or adverse response to naltrexone.

6. History of drug or alcohol abuse (>80 g/day).

7. History of sleep apnea or restless leg syndrome.

8. Serology positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies.

9. Positive for known disease (e.g., corona virus disease 2019 (COVID-19 )).

10. Subjects with current or past SARS-CoV-2 infection, if tested according to local requirements.

11. Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: missed work in itself may not denote serious illness).

12. Have cancer within the past 5 years (treated or untreated).

13. Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding.

14. Are an employee, family member, sponsor, or student of the Investigator or of the clinical site.

15. Are unable to understand or adhere to the requirements of the protocol.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• SP-104
oral capsule once daily
• Naltrexone immediate release oral capsules
oral capsule once daily

Locations

Country	Name	City	State
New Zealand	Auckland Clinical Studies (NZCR)	Auckland
New Zealand	Christchurch Clinical Studies Trust (NZCR)	Christchurch

Sponsors (1)

Lead Sponsor	Collaborator
Scilex Pharmaceuticals, Inc.

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment emergent adverse events		1 week